Last 47 quarters of trend data · Healthcare · Neuroscience Biotech
Quarterly valuation ratios — annualised for comparability. YoY Δ shows same-quarter-prior-year change.
| Metric | TTM | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio → | -4.37 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| P/S Ratio | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| P/B Ratio | 1.03 | 2.11 | 2.34 | 2.50 | 8.06 | 8.65 | 7.32 | 8.21 | 3.97 | 2.75 | 3.10 | 5.64 | 3.68 | 4.48 | 4.62 | 5.34 | 5.57 | 5.14 | 6.17 | 9.00 | 9.05 |
| — | -75.7% | -68.1% | -69.5% | +103.1% | +214.9% | +135.7% | +45.7% | +7.7% | -38.6% | -32.8% | +5.5% | -33.9% | -12.9% | -25.0% | -40.6% | -38.4% | -49.9% | -54.4% | +20.1% | -15.8% | |
| P/FCF | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Quarterly margins and returns. Watch for margin compression across consecutive quarters.
| Metric | TTM | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Operating Margin | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Net Margin | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Metric | TTM | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -43.1% | -2.7% | -4.3% | -5.1% | -10.6% | -13.9% | -10.6% | -10.5% | -9.3% | -9.2% | -7.8% | -6.2% | -7.0% | -7.7% | -9.4% | -9.3% | -9.7% | -8.2% | -7.0% | -7.3% | -7.6% |
| — | +80.3% | +59.6% | +51.0% | -13.8% | -50.6% | -36.4% | -68.6% | -32.2% | -19.3% | +16.7% | +33.5% | +27.9% | +5.3% | -33.8% | -27.6% | -28.1% | +6.6% | +47.7% | +65.7% | +66.9% | |
| ROA | -38.7% | -2.6% | -4.1% | -4.8% | -9.5% | -12.1% | -9.3% | -9.3% | -8.4% | -8.5% | -7.2% | -5.7% | -6.5% | -7.1% | -8.5% | -8.6% | -9.1% | -7.7% | -6.6% | -6.8% | -7.1% |
| — | +78.7% | +56.1% | +48.6% | -13.6% | -41.4% | -28.9% | -63.6% | -29.0% | -19.9% | +15.5% | +33.8% | +28.8% | +7.8% | -29.5% | -26.1% | -27.8% | +5.2% | +44.3% | +61.3% | +60.4% | |
| ROIC | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Quarterly solvency trend — watch for debt spikes or covenant pressure.
| Metric | TTM | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Current Ratio | 11.60 | 15.62 | 18.24 | 20.87 | 11.60 | 8.82 | 6.74 | 9.45 | 8.86 | 12.04 | 15.12 | 11.85 | 12.32 | 14.27 | 11.35 | 11.20 | 14.95 | 16.89 | 19.86 | 14.90 | 14.97 |
| — | +77.1% | +170.7% | +120.9% | +31.0% | -26.8% | -55.4% | -20.3% | -28.1% | -15.6% | +33.2% | +5.8% | -17.6% | -15.5% | -42.8% | -24.8% | -0.1% | -5.9% | +84.5% | +120.3% | +216.5% | |
| Quick Ratio | 11.60 | 15.62 | 18.24 | 20.87 | 11.60 | 8.82 | 6.74 | 9.45 | 8.86 | 12.04 | 15.12 | 11.85 | 12.32 | 14.27 | 11.35 | 11.20 | 14.95 | 16.89 | 19.86 | 14.90 | 14.97 |
| — | +77.1% | +170.7% | +120.9% | +31.0% | -26.8% | -55.4% | -20.3% | -28.1% | -15.6% | +33.2% | +5.8% | -17.6% | -15.5% | -42.8% | -24.8% | -0.1% | -5.9% | +84.5% | +120.3% | +216.5% | |
| Interest Coverage | — | — | — | — | — | — | — | — | — | — | — | — | — | — | -12.54 | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Includes 30+ ratios · 47 years · Updated daily
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying AVXL stock.
Anavex Life Sciences Corp.'s current P/E is -4.4x. Quarterly P/E ratios can vary due to seasonal revenue patterns and one-time charges.
Quarterly financial ratios reveal short-term trend shifts — margin compression, debt spikes, or valuation re-ratings — that annual figures smooth over. They're essential for active investors tracking Anavex Life Sciences Corp.'s business trajectory between earnings reports.